Wenzel, B.; Fritzsche, S.R.; Toussaint, M.; Briel, D.; Kopka, K.; Brust, P.; Scheunemann, M.; Deuther-Conrad, W.
Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A). Pharmaceuticals 2022, 15, 1272.
https://doi.org/10.3390/ph15101272
AMA Style
Wenzel B, Fritzsche SR, Toussaint M, Briel D, Kopka K, Brust P, Scheunemann M, Deuther-Conrad W.
Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A). Pharmaceuticals. 2022; 15(10):1272.
https://doi.org/10.3390/ph15101272
Chicago/Turabian Style
Wenzel, Barbara, Stefan R. Fritzsche, Magali Toussaint, Detlef Briel, Klaus Kopka, Peter Brust, Matthias Scheunemann, and Winnie Deuther-Conrad.
2022. "Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)" Pharmaceuticals 15, no. 10: 1272.
https://doi.org/10.3390/ph15101272
APA Style
Wenzel, B., Fritzsche, S. R., Toussaint, M., Briel, D., Kopka, K., Brust, P., Scheunemann, M., & Deuther-Conrad, W.
(2022). Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A). Pharmaceuticals, 15(10), 1272.
https://doi.org/10.3390/ph15101272
